Stoke presents STK-001 data at AES 2023: seizure reductions and cognition gains in Dravet syndrome

Stoke Therapeutics, Inc.

Higher STK-001 brain exposure linked to greater seizure reductions in 72 patients (R=-0.23, P<0.001).
Multiple 70mg doses of STK-001 showed the largest reductions in convulsive seizure frequency.
90% of Phase 1/2a completers enrolled in open-label extension studies (SWALLOWTAIL & LONGWING).
BUTTERFLY natural history study: patients on ~3.5 anti-seizure drugs saw no meaningful seizure improvement over 2 years.
OLE data showed substantial improvements in cognition and behavior over 12 months, supporting disease modification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.